Understanding and Anticipating Therapeutic Response And Immuno-meDIated Adverse Events in Anti-cancer Immune-checkpoint Inhibition: a Tissue Biopsy Based imaGing Study

Launched by UNIVERSITY HOSPITAL, BREST · Jun 26, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring how certain cancer treatments called immune checkpoint inhibitors (ICIs) work and the potential side effects they can cause. ICIs help the immune system fight cancer more effectively, but they don't work for everyone and can sometimes lead to serious side effects known as immune-related adverse events (irAEs). The goal of this study is to look closely at the immune cells in both tumors and tissues affected by these side effects to better understand who might benefit from ICIs and who might experience these adverse effects.

To participate in this trial, you need to be at least 18 years old and have been treated with an immune checkpoint inhibitor for advanced cancer at specific hospitals in France. You must also have a tumor or tissue sample available for testing. Participants will undergo analyses using advanced technology to help researchers learn more about the immune response related to cancer treatment and side effects. This research aims to improve treatment strategies and manage side effects more effectively in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old
• • Treated by Immune checkpoint inhibitor (ICI) for an advanced cancer
• • Treated at Brest University-Hospital, Morlaix Hospital, Quimper Hospital, Clinique Pasteur in Brest or Bordeaux University Hospital
• • With a tumor or tissue biopsy (organ target of irAEs) archived in sufficient quantity for Hyperion analysis
• • For the control group: patient with an inflammatory disease (autoimmune, autoinflammatory) who had a biopsy at diagnosis
• Exclusion Criteria:
• • Subject of guardianship (tutorship, curatorship)
• • Refusal to participate
• • Patient not meeting inclusion criteria for each point